JP2018508509A5 - - Google Patents

Download PDF

Info

Publication number
JP2018508509A5
JP2018508509A5 JP2017544293A JP2017544293A JP2018508509A5 JP 2018508509 A5 JP2018508509 A5 JP 2018508509A5 JP 2017544293 A JP2017544293 A JP 2017544293A JP 2017544293 A JP2017544293 A JP 2017544293A JP 2018508509 A5 JP2018508509 A5 JP 2018508509A5
Authority
JP
Japan
Prior art keywords
antibody
cancer
fully human
seq
fab fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017544293A
Other languages
English (en)
Other versions
JP2018508509A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/018897 external-priority patent/WO2016134358A1/en
Publication of JP2018508509A publication Critical patent/JP2018508509A/ja
Publication of JP2018508509A5 publication Critical patent/JP2018508509A5/ja
Withdrawn legal-status Critical Current

Links

Claims (11)

  1. 配列番号１４３／配列番号２８（ＭＳＨ１）の重鎖／軽鎖可変ドメイン配列を含む、ＣＤ１３７エピトープに結合するＩｇＧクラスの単離された完全ヒト抗ＣＤ１３７抗体。
  2. 抗体が少なくとも１×１０−６ＭのＫＤを有する、請求項１に記載の完全ヒト抗体。
  3. 抗ＣＤ１３７完全ヒト抗体Ｆａｂ断片であって、抗体が、配列番号１４３／配列番号２８の重鎖／軽鎖可変ドメイン配列を含む、抗ＣＤ１３７完全ヒト抗体Ｆａｂ断片。
  4. 抗体が少なくとも１×１０−６ＭのＫＤを有する、請求項３に記載の完全ヒト抗体Ｆａｂ断片。
  5. 配列番号１４３／配列番号２８の重鎖／軽鎖可変ドメイン配列を含む、ペプチドリンカーによって連結された重鎖可変ドメインおよび軽鎖可変ドメインを含む抗ＣＤ１３７一本鎖完全ヒト抗体。
  6. 抗体が少なくとも１×１０−６ＭのＫＤを有する、請求項５に記載の完全ヒト一本鎖抗体。
  7. 請求項１から６のいずれか一項に記載の有効量の抗体、抗体Ｆａｂ断片、または一本鎖完全ヒト抗体を含み、それによりがんが治療される、がんを治療するための医薬。
  8. がんが、卵巣がん、結腸直腸がん、黒色腫、肝細胞がん、腎臓がん、乳がん、頭頸部がん、肺がんおよび肝臓がんからなる群から選択される、請求項７に記載の医薬。
  9. 請求項１から６のいずれか一項に記載の有効量の抗体、抗体Ｆａｂ断片、または一本鎖完全ヒト抗体を含む、免疫応答の刺激または免疫応答の抑制のいずれかを必要とする疾患を治療するための医薬。
  10. 疾患が、がん、自己免疫疾患およびウイルス感染からなる群から選択される、請求項９に記載の医薬。
  11. 請求項１から６のいずれか一項に記載の抗ＣＤ１３７抗体、抗体Ｆａｂ断片、または一本鎖完全ヒト抗体、および医薬として許容される担体を含む医薬組成物。
JP2017544293A 2015-02-22 2016-02-22 Ｃｄ１３７に結合する抗体医薬 Withdrawn JP2018508509A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562119211P 2015-02-22 2015-02-22
US62/119,211 2015-02-22
PCT/US2016/018897 WO2016134358A1 (en) 2015-02-22 2016-02-22 Antibody therapeutics that bind cd137

Publications (2)

Publication Number Publication Date
JP2018508509A JP2018508509A (ja) 2018-03-29
JP2018508509A5 true JP2018508509A5 (ja) 2019-04-04

Family

ID=56690285

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017544293A Withdrawn JP2018508509A (ja) 2015-02-22 2016-02-22 Ｃｄ１３７に結合する抗体医薬

Country Status (12)

Country Link
US (4) US10259881B2 (ja)
EP (1) EP3258959A4 (ja)
JP (1) JP2018508509A (ja)
KR (1) KR20180016972A (ja)
CN (1) CN107921104A (ja)
AR (1) AR105313A1 (ja)
AU (1) AU2016219772A1 (ja)
CA (1) CA2977257A1 (ja)
IL (1) IL254088A0 (ja)
MX (1) MX2017010793A (ja)
TW (1) TW201632559A (ja)
WO (1) WO2016134358A1 (ja)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
EP3258959A4 (en) 2015-02-22 2018-10-17 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137
EP3988577A1 (en) * 2015-05-21 2022-04-27 Alligator Bioscience AB Anti-cd137 antibodies
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
MA45672A (fr) 2016-07-14 2019-05-22 Biontech Ag Anticorps multispécifiques dirigés contre cd40 et cd137
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
GB201619648D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
WO2018098370A1 (en) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
EP3523332B1 (en) * 2017-01-06 2021-12-29 Eutilex Co., Ltd. Anti-human 4-1 bb antibodies and use thereof
CN109963570A (zh) 2017-01-21 2019-07-02 宁波知明生物科技有限公司 芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
MX2019012223A (es) * 2017-04-13 2019-12-09 Agenus Inc Anticuerpos anti-cd137 y metodos de uso de los mismos.
TWI820031B (zh) 2017-07-11 2023-11-01 美商坎伯斯治療有限責任公司 結合人類cd137之促效劑抗體及其用途
BR112020001441A2 (pt) 2017-08-01 2020-08-04 Eli Lilly And Company anticorpos anti-cd137
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. ANTI-CD137 MOLECULES AND THEIR USE
SG11202002982YA (en) * 2017-10-10 2020-04-29 Numab Therapeutics AG Multispecific antibody
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
TWI701259B (zh) * 2017-11-09 2020-08-11 大陸商上海懷越生物科技有限公司 ４﹘１ｂｂ抗體及其製備方法和應用
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019104716A1 (en) * 2017-12-01 2019-06-06 Adagene Inc. Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
CN111741976A (zh) 2017-12-19 2020-10-02 F星贝塔有限公司 包括pd-l1抗原结合位点的fc结合片段
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
BR112020014576A2 (pt) * 2018-02-23 2020-12-08 Bicycletx Limited Ligantes peptídicos bicíclicos multiméricos
CA3099308A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
EP3814377A2 (en) * 2018-06-29 2021-05-05 Alector LLC Anti-sirp-beta1 antibodies and methods of use thereof
EP3823988A1 (en) * 2018-07-19 2021-05-26 Eli Lilly and Company Bispecific antibodies targeting immune checkpoints
WO2020052581A1 (en) 2018-09-12 2020-03-19 Eucure (Beijing) Biopharma Co., Ltd Anti-tnfrsf9 antibodies and uses thereof
CN113166262A (zh) 2018-10-11 2021-07-23 英伊布里克斯公司 Pd-1单结构域抗体及其治疗组合物
CN113286825B (zh) * 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途
EP3906056A4 (en) * 2019-01-02 2023-02-08 QLSF Biotherapeutics Inc. CD137 AGONIST ANTIBODIES AND USES THEREOF
MX2021010281A (es) * 2019-02-26 2021-09-23 Sorrento Therapeutics Inc Proteinas de enlace a antigenos que se enlazan al bcma.
US20230135930A1 (en) 2019-04-24 2023-05-04 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
EP3980448A4 (en) * 2019-06-04 2023-06-28 Academia Sinica Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors
CA3144617A1 (en) * 2019-06-26 2020-12-30 Ap Biosciences, Inc. Antibodies for t-cell activation
US11466086B2 (en) 2019-10-11 2022-10-11 Nanjing Leads Biolabs Co., Ltd. Antibodies binding 4-1BB and uses thereof
US20230068663A1 (en) * 2020-02-05 2023-03-02 The Board Of Regents Of The University Of Texas System Novel lilrb2 antibodies and uses thereof
US20230285555A1 (en) * 2020-04-17 2023-09-14 Dingfu Biotarget, Co., Ltd. Preparation specifically bound with cd137 and use thereof
CN113842456B (zh) * 2020-06-28 2022-07-26 上海齐鲁制药研究中心有限公司 一种抗人4-1bb的单克隆抗体制剂及其用途
WO2023098785A1 (zh) * 2021-12-01 2023-06-08 上海君实生物医药科技股份有限公司 抗4-1bb抗体及其用途
CN115975032B (zh) * 2022-12-19 2024-06-07 华润生物医药有限公司 一种cldn18.2抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (en) * 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
ES2328025T3 (es) * 2001-10-09 2009-11-06 Mayo Foundation For Medical Education And Research Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb.
US20030223989A1 (en) * 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP1851244A4 (en) 2005-02-15 2009-04-15 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF
PL2614082T3 (pl) * 2010-09-09 2019-02-28 Pfizer Inc. Cząsteczki wiążące 4-1BB
PT2644698T (pt) * 2010-11-17 2018-01-31 Chugai Pharmaceutical Co Ltd Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP3258959A4 (en) 2015-02-22 2018-10-17 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137
TW201639888A (zh) 2015-03-06 2016-11-16 索倫多醫療公司 結合ｔｉｍ３之抗體治療劑
CN112789294A (zh) * 2018-07-24 2021-05-11 印希比股份有限公司 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
CN113166262A (zh) * 2018-10-11 2021-07-23 英伊布里克斯公司 Pd-1单结构域抗体及其治疗组合物

Similar Documents

Publication Publication Date Title
JP2018508509A5 (ja)
JP2018510147A5 (ja)
JP2019506841A5 (ja)
JP2018510151A5 (ja)
HRP20161740T1 (hr) Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b
JP2016502515A5 (ja)
JP2018508573A5 (ja)
JP2019513777A5 (ja)
RU2013102225A (ru) АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2017501167A5 (ja)
JP2019535763A5 (ja)
AR109298A1 (es) Anticuerpos multiepitópicos y multivalentes que tienen actividad agonista y métodos de uso
JP2018510865A5 (ja)
RU2018139811A (ru) Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства
JP2018108086A5 (ja)
JP2016503413A5 (ja)
JP2013538553A5 (ja)
JP2017517499A5 (ja)
RU2017102514A (ru) Гуманизированные анти-тау-антитела
JP2014522843A5 (ja)
JP2016507555A5 (ja)
JP2012525128A5 (ja)
JP2015502138A5 (ja)
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
JP2009505676A5 (ja)